(Reuters) -Drugmaker AbbVie said on Friday it has lowered its annual profit forecast, after a flagging an expected $2.7 billion charge related to in-process research and development (IPR&D) expenses in the third quarter. Shares of the North Chicago-based company were down nearly 1% at $232.0 in extended trade. AbbVie said in a regulatory filing that such expenses may arise from collaborations, licensing deals or asset buys, but are not forecast due to uncertainty around timing and occurrence. It did not specify how the expense was incurred. Including the third-quarter charge, AbbVie now expects full-year adjusted earnings per share between $10.38 and $10.58, compared with the prior range of $11.88 to $12.08. Analysts were expecting full-year adjusted EPS to be $12.02, according to data com

See Full Page